Prognostic Value of the Systemic Immune-Inflammation Index in Patients With Acute Myocardial Infarction: A Systematic Review and Meta-Analysis.
Yangmei Du, Xing Deng, Yanping Song et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis assessed whether the Systemic Immune-Inflammation Index (SII) predicts outcomes in patients with acute myocardial infarction (AMI). It included 21 studies and 13 771 patients with STEMI or NSTEMI. Higher SII was associated with greater odds of major adverse cardiovascular events (MACE) (OR: 1.09; 95% CI: 1.04-1.13; P < .0001). The association with MACE was significant in STEMI but not NSTEMI. Elevated SII was also associated with no-reflow after PCI, left ventricular adverse remodeling, and all-cause mortality.
Key findings
- Across AMI studies, higher SII was associated with increased MACE odds (OR: 1.09; 95% CI: 1.04-1.13; P < .0001).
- Elevated SII was significantly associated with MACE in STEMI patients, but not in NSTEMI patients.
- High SII was associated with no-reflow after PCI, left ventricular adverse remodeling, and all-cause mortality.
Why it matters
The findings suggest that SII, an inflammation-related index, may help identify AMI patients at higher risk of adverse outcomes, particularly those with STEMI. Risk stratification could support closer assessment of prognosis, but the reported associations do not establish that SII causes these outcomes or that acting on the index improves them.
What to keep in mind
The meta-analysis combines studies with different designs and populations; the abstract reports heterogeneity assessment but does not provide details on outcome definitions or the underlying studies’ limitations.